AlloVir (NASDAQ: ALVR)
Some price data may be temporarily unavailable.
AlloVir Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
AlloVir Company Info
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
News & Analysis
Why AlloVir Stock Dropped Today
AlloVir briefly plunged amid concerns over selling pressure related to a recent lock-up agreement expiration.
Why Shares of AlloVir Plummeted This Week
The clinical-stage biotech's shares fell after the company announced a stock sale.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.